For HER2 + cases, the proportion of PRs and IRs did not differ until ER levels were at least 20%, but given the small number of HER2 + cases in the individual lower ER categories there was no clear evidence for different cut-points for HER2 + and HER2 − tumours (Fig. 1B and C). Here, ERBB2 is linked to neoplasm.